Anbieter: Ammareal, Morangis, Frankreich
Hardcover. Zustand: Très bon. Ancien livre de bibliothèque avec équipements. Edition 2002. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 2002. Ammareal gives back up to 15% of this item's net price to charity organizations.
Anbieter: Anybook.com, Lincoln, Vereinigtes Königreich
EUR 35,11
Anzahl: 1 verfügbar
In den WarenkorbZustand: Good. Volume 93. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings. In good all round condition. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,900grams, ISBN:9783764360818.
Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 308 | Sprache: Englisch | Produktart: Bücher | Research in the pharmaceutical industry today is in many respects quite different from what it used to be only fifteen years ago. There have been dramatic changes in approaches for identifying new chemical entities with a desired biological activity. While chemical modification of existing leads was the most important approach in the 1970s and 1980s, high-throughput screening and structure-based design are now major players among a multitude of methods used in drug discov ery. Quite often, companies favor one of these relatively new approaches over the other, e.g., screening over rational design, or vice versa, but we believe that an intelligent and concerted use of several or all methods currently available to drug discovery will be more successful in the medium term. What has changed most significantly in the past few years is the time available for identifying new chemical entities. Because of the high costs of drug discovery projects, pressure for maximum success in the shortest possible time is higher than ever. In addition, the multidisciplinary character of the field is much more pronounced today than it used to be. As a consequence, researchers and project managers in the pharmaceutical industry should have a solid knowledge of the more important methods available to drug discovery, because it is the rapidly and intelligently combined use of these which will determine the success or failure of preclinical projects.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 164,21
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Research in the pharmaceutical industry today is in many respects quite different from what it used to be only fifteen years ago. There have been dramatic changes in approaches for identifying new chemical entities with a desired biological activity. While chemical modification of existing leads was the most important approach in the 1970s and 1980s, high-throughput screening and structure-based design are now major players among a multitude of methods used in drug discov ery. Quite often, companies favor one of these relatively new approaches over the other, e.g., screening over rational design, or vice versa, but we believe that an intelligent and concerted use of several or all methods currently available to drug discovery will be more successful in the medium term. What has changed most significantly in the past few years is the time available for identifying new chemical entities. Because of the high costs of drug discovery projects, pressure for maximum success in the shortest possible time is higher than ever. In addition, the multidisciplinary character of the field is much more pronounced today than it used to be. As a consequence, researchers and project managers in the pharmaceutical industry should have a solid knowledge of the more important methods available to drug discovery, because it is the rapidly and intelligently combined use of these which will determine the success or failure of preclinical projects.
Zustand: New. Offers an interdisciplinary view of modern approaches to drug discovery as used by pharmaceutical companies and research institutes. This book comprehensively covers proteomics, bioinformatics, screening techniques such as high-throughput, natural compounds, and NMR-based-screenings, combinatorial chemistry, and compound library design. Editor(s): Hillisch, Alexander; Hilgenfeld, Rolf. Series: Experientia Supplementum. Num Pages: 292 pages, biography. BIC Classification: KNDP; MMG; TDCW. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 235 x 155 x 21. Weight in Grams: 800. . 2002. Hardback. . . . . Books ship from the US and Ireland.